Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Phalanx Distribution Partnership
Voyageur Pharmaceuticals has signed a non-exclusive distribution agreement with Mexican company Phalanx to expand access to its barium-based contrast media products in Latin America, representing a strategic move to address growing demand for cost-effective medical imaging solutions in underserved markets.
Voyageur Pharmaceuticals Ltd. has entered into a non-exclusive distribution agreement with Mexican company PHALANX, Comercializadora e Importadora de Componentes SA DE CV, marking a significant expansion into Latin American healthcare markets. The agreement follows a non-binding Letter of Intent announced on June 24, 2025, and establishes a strategic partnership focused on market expansion within Mexico's medical imaging and contrast media sectors.
Under the distribution framework, Phalanx will register Voyageur's barium contrast media products with Mexican health regulatory authorities and distribute them through its established network. Voyageur will provide comprehensive support throughout the regulatory approval and commercialization process. This partnership represents a key milestone in Voyageur's international growth strategy, expanding the company's global footprint while addressing increasing demand for high-quality contrast media in underserved markets.
Brent Willis, CEO of Voyageur, emphasized the strategic importance of this development, stating that it reflects the company's commitment to expanding global access to innovative, cost-effective imaging solutions. Latin America represents a critical market in Voyageur's expansion plan, with this partnership establishing groundwork for long-term growth. The company's approach aligns with its broader vision of becoming the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw material sourcing to final production.
Phalanx brings substantial expertise to the partnership, with over 20 years of experience in iodine and gadolinium contrast media for radiology. The company provides comprehensive commercial intelligence and strategic market solutions for businesses entering Latin American markets. Through its website at https://voyageurpharmaceuticals.ca, Voyageur maintains transparency about its operations and development progress. Sales of Voyageur's barium sulfate contrast media products in Mexico and other Latin American countries remain subject to local regulatory approval processes, with Phalanx taking the lead in preparing and submitting necessary filings supported by Voyageur's technical and regulatory team.
The partnership leverages Phalanx's deep regulatory expertise and supply chain management capabilities to accelerate international expansion while minimizing risk. This collaboration enables Voyageur to establish a compliant presence across Latin America, particularly in markets that recognize Canadian regulatory approvals. The company's Frances Creek Project, which features rare high-grade mineral suitable for pharmaceutical applications, positions Voyageur to potentially replace current synthetic barium sulfate products with higher quality imaging alternatives.